Stephanie Kenney
CIK: 0002105422
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RNA
Atrium Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Kenney Stephanie
Kenney Stephanie (SEC CIK 0002105422) files insider reports with the SEC as Officer of Atrium Therapeutics, Inc. (RNA).
Signal8 holds 3 ownership filings by Kenney Stephanie (1 Form 3, 2 Form 4), filed between Feb 26, 2026 and Sep 22, 2026. Those filings report 2 transactions, from Apr 20, 2026 to Sep 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kenney Stephanie's filings is in SAN DIEGO, CA.
Recent filings by Kenney Stephanie
Other insiders filing for Atrium Therapeutics, Inc. (RNA)
- Younis Husam, Chief Scientific Officer
- Hughes Steven George, Chief Medical Officer
- Flanagan W. Michael, Director
- Boyce Sarah, Director
- Gallagher Kathleen P.
- Winslow Brendan R., Chief Financial Officer